BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30113764)

  • 21. The knowledge on the 3rd type hematogones could contribute to more precise detection of small numbers of precursor B-acute lymphoblastic leukemia.
    Babusíková O; Zelezníková T; Mlcáková A; Kusenda J; Stevulová L
    Neoplasma; 2005; 52(6):502-9. PubMed ID: 16284697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia.
    Veltroni M; De Zen L; Sanzari MC; Maglia O; Dworzak MN; Ratei R; Biondi A; Basso G; Gaipa G;
    Haematologica; 2003 Nov; 88(11):1245-52. PubMed ID: 14607753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
    Mikhailova E; Semchenkova A; Illarionova O; Kashpor S; Brilliantova V; Zakharova E; Zerkalenkova E; Zangrando A; Bocharova N; Shelikhova L; Diakonova Y; Zhogov V; Khismatullina R; Molostova O; Buldini B; Raykina E; Larin S; Olshanskaya Y; Miakova N; Novichkova G; Maschan M; Popov AM
    Br J Haematol; 2021 May; 193(3):602-612. PubMed ID: 33715150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of CD34/CD123 expression in detection of minimal residual disease in B-ACUTE lymphoblastic leukemia in children.
    Zeidan MA; Kamal HM; El Shabrawy DA; Esh AM; Sattar RH
    Blood Cells Mol Dis; 2016 Jul; 59():113-8. PubMed ID: 27282579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD38+ CD58- is an independent adverse prognostic factor in paediatric Philadelphia chromosome negative B cell acute lymphoblastic leukaemia patients.
    Li XM; Zhang LP; Wang YZ; Lu AD; Chang Y; Zhu HH; Qin YZ; Lai YY; Kong Y; Huang XJ; Liu YR
    Leuk Res; 2016 Apr; 43():33-8. PubMed ID: 26930456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia.
    Verbeek MWC; van der Velden VHJ
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia.
    Seegmiller AC; Kroft SH; Karandikar NJ; McKenna RW
    Am J Clin Pathol; 2009 Dec; 132(6):940-9. PubMed ID: 19926587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The significance of peripheral blood minimal residual disease to predict early disease response in patients with B-cell acute lymphoblastic leukemia.
    Setiadi A; Owen D; Tsang A; Milner R; Vercauteren S
    Int J Lab Hematol; 2016 Oct; 38(5):527-34. PubMed ID: 27339737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases.
    Raponi S; De Propris MS; Intoppa S; Milani ML; Vitale A; Elia L; Perbellini O; Pizzolo G; Foá R; Guarini A
    Leuk Lymphoma; 2011 Jun; 52(6):1098-107. PubMed ID: 21348573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunophenotypic analysis of bone marrow B lymphocyte precursors (hématogones) by flow cytometry.
    Braham Jmili N; Nsaibia S; Jacob MC; Omri H; Laatiri MA; Yacoub S; Braham Y; Aouni M; Kortas M
    Clin Lab Sci; 2009; 22(4):208-15. PubMed ID: 19967915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [CD34(+)CD19(+) cells with CD123 overexpression are a novel prognostic marker in Ph chromosome-positive acute lymphoblastic leukemia].
    Kong Y; Huang XJ; Hao L; Qin YZ; Jiang Q; Jiang H; Liu YR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):6-10. PubMed ID: 24598641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuropilin-1/CD304 Expression by Flow Cytometry in Pediatric Precursor B-Acute Lymphoblastic Leukemia: A Minimal Residual Disease and Potential Prognostic Marker.
    Abaza HM; Alfeky MAA; Eissa DS; Abdel Fattah MF; Annaka LM; Ebeid FS
    J Pediatr Hematol Oncol; 2018 Apr; 40(3):200-207. PubMed ID: 29200164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression of CD58 in childhood B-lineage acute lymphoblastic leukemia and its feasibility in minimal residual disease detection].
    Li YF; Zhao XM; Sheng GY; Yue BH; Luo Y
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Aug; 17(8):825-9. PubMed ID: 26287347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Flow cytometric characterization of maturation processes and primitive stem cell population in pre-B-cell ALL in childhood].
    Baersch G; Baumann M; Meltzer J; Möllers T; Ritter J; Jürgens H; Vormoor J
    Klin Padiatr; 1996; 208(4):160-7. PubMed ID: 8926682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunophenotypic analysis of CD19+ precursors in normal human adult bone marrow: implications for minimal residual disease detection.
    Ciudad J; Orfao A; Vidriales B; Macedo A; Martínez A; González M; López-Berges MC; Valverde B; San Miguel JF
    Haematologica; 1998 Dec; 83(12):1069-75. PubMed ID: 9949623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prognostic significance of lymphocyte function associated anti-gen-3 (CD58) in childhood B cell-acute lymphocytic leukemia].
    Xu C; Zhao HJ; Jiang LM; Yuan XJ; Li L; Tang JY; Shen LS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):717-21. PubMed ID: 16928307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: a study of five cases controlled by genetic methods.
    Dworzak MN; Stolz F; Fröschl G; Printz D; Henn T; Fischer S; Fleischer C; Haas OA; Fritsch G; Gadner H; Panzer-Grümayer ER
    Exp Hematol; 1999 Apr; 27(4):673-81. PubMed ID: 10210325
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.
    Angelova E; Audette C; Kovtun Y; Daver N; Wang SA; Pierce S; Konoplev SN; Khogeer H; Jorgensen JL; Konopleva M; Zweidler-McKay PA; Medeiros LJ; Kantarjian HM; Jabbour EJ; Khoury JD
    Haematologica; 2019 Apr; 104(4):749-755. PubMed ID: 30361418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Presence of CD34(+)CD38(-)CD58(-) leukemia-propagating cells at diagnosis identifies patients at high risk of relapse with Ph chromosome-positive ALL after allo-hematopoietic SCT.
    Kong Y; Xu LP; Liu YR; Qin YZ; Sun YQ; Wang Y; Jiang H; Jiang Q; Chen H; Chang YJ; Huang XJ
    Bone Marrow Transplant; 2015 Mar; 50(3):348-53. PubMed ID: 25486581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinct expression patterns of CD123 and CD34 on normal bone marrow B-cell precursors ("hematogones") and B lymphoblastic leukemia blasts.
    Hassanein NM; Alcancia F; Perkinson KR; Buckley PJ; Lagoo AS
    Am J Clin Pathol; 2009 Oct; 132(4):573-80. PubMed ID: 19762535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.